Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Vamikibart?
Vamikibart is a monoclonal antibody commercialized by Roche, with a leading Phase III program in Uveitis. According to Globaldata, it...
Vamikibart by F. Hoffmann-La Roche for Diabetic Macular Edema: Likelihood of Approval
Vamikibart is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Diabetic Macular Edema. According to...
Vamikibart by F. Hoffmann-La Roche for Uveitis: Likelihood of Approval
Vamikibart is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Uveitis. According to GlobalData, Phase...